drugset / Trial / NCT00521404
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.
Timeline
- Start
- 2007-08-15
- Primary completion
- 2010-08-20
- Completion
- 2010-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tigatuzumab | Monoclonal antibody | 3 mg/kg | — |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |